Search Results

You are looking at 31 - 40 of 44 items for :

  • "nephrectomy" x
  • User-accessible content x
Clear All
Full access

James Brugarolas

) samples (largely from archival nephrectomy specimens) were subjected to whole-exome sequencing. The authors found polybromo 1 ( PBRM1 ) mutations enriched in tumors from the responding group (7 of 13 vs 1 of 14; unadjusted P =.01). These results are

Full access

Andre P. Fay, Guillermo de Velasco, Thai H. Ho, Eliezer M. Van Allen, Bradley Murray, Laurence Albiges, Sabina Signoretti, A. Ari Hakimi, Melissa L. Stanton, Joaquim Bellmunt, David F. McDermott, Michael B. Atkins, Levi A. Garraway, David J. Kwiatkowski and Toni K. Choueiri

(n=14). We performed WES in pretreatment formalin-fixed, paraffin-embedded samples (90% nephrectomies [n=18] and 10% lung metastases [n=2]) from 20 patients treated with sunitinib or pazopanib at Dana-Farber Cancer Institute. We also included 7

Full access

Eric Jonasch and Robert J. Motzer

, endothelial, and stromal compartments as a function of therapy. Trial designs that permit acquisition of useful material include presurgical and sequential studies. The former can acquire nephrectomy specimens that have undergone changes as a function of

Full access

Elio Mazzone, Sophie Knipper, Francesco A. Mistretta, Carlotta Palumbo, Zhe Tian, Andrea Gallina, Derya Tilki, Shahrokh F. Shariat, Francesco Montorsi, Fred Saad, Alberto Briganti and Pierre I. Karakiewicz

S , Preisser F , . Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma . Cancer Epidemiol 2018 ; 56 : 118 – 125 . 10.1016/j.canep.2018.08.006 26. Abdollah F , Sammon

Full access

Jilma Patrick and Seema Ahsan Khan

the primary tumor. These studies include a randomized trial of patients with stage IV renal cell carcinoma that demonstrated a modest but significant survival advantage for the nephrectomy group. 3 Improved survival with resection of primary disease

Full access

Neil K. Taunk, Daniel E. Spratt, Mark Bilsky and Yoshiya Yamada

2003 to 2009. 1 At presentation, 25% of patients will demonstrate metastases, and 25% who undergo nephrectomy for localized disease will ultimately develop recurrent or metastatic tumor. 1 Targeted therapies directed against vascular endothelial

Full access

Pablo Maroto, Georgia Anguera, Juan Maria Roldan-Romero, Maria Apellániz-Ruiz, Ferran Algaba, Jacqueline Boonman, Mark Nellist, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo and Cristina Rodríguez-Antona

2009, a right nephrectomy was performed. Pathologic studies confirmed a renal carcinoma, pT1b. The patient was disease-free and continued temsirolimus until September 2011, when Figure 1. Histologic findings and CT scans. (A) Hematoxylin

Full access

Juan Francisco Rodríguez-Moreno, María Apellaniz-Ruiz, Juan María Roldan-Romero, Ignacio Durán, Luis Beltrán, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, Jesus García-Donas and Cristina Rodríguez-Antona

initial diagnosis was pT1bN0M1 (stage IV). In April 2007, an open right radical nephrectomy was performed. The histopathologic report revealed Fuhrman grade 4 advanced ccRCC. According to the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic model

Full access

Pamala A. Pawloski, Gabriel A. Brooks, Matthew E. Nielsen and Barbara A. Olson-Bullis

. Chang PL , Li YC , Lee SH. The differences in health outcomes between Web-based and paper-based implementation of a clinical pathway for radical nephrectomy . BJU Int 2002 ; 90 : 522 – 528 . 12230609 10.1046/j.1464-410X.2002.02980.x 35. Hsu

Full access

After Radical Nephrectomy Todd M. Morgan, MD a ; Rohit Mehra, MD a ; Placede Tiemeny, PhD b ; J. Stuart Wolf, MD a ; Steven Stone, PhD b ; Chin-Lee Wu, MD c ; and Adam S. Feldman, MD c From a University of Michigan Comprehensive Cancer Center, b